Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy

I. Vidlickova, F. Dequiedt, L. Jelenska, O. Sedlakova, M. Pastorek, S. Stuchlik, J. Pastorek, M. Zatovicova, S. Pastorekova,

. 2016 ; 16 (-) : 239. [pub] 20160319

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000331

BACKGROUND: Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it can signify cancer prognosis. We previously showed that the CA IX ECD release is mediated by disintegrin and metalloproteinase ADAM17. Here we investigated the CA IX ECD shedding in tumor cells undergoing apoptosis in response to cytotoxic drugs, including cycloheximide and doxorubicin. METHODS: Presence of cell surface CA IX was correlated to the extent of apoptosis by flow cytometry in cell lines with natural or ectopic CA IX expression. CA IX ECD level was assessed by ELISA using CA IX-specific monoclonal antibodies. Effect of recombinant CA IX ECD on the activation of molecular pathways was evaluated using the cell-based dual-luciferase reporter assay. RESULTS: We found a significantly lower occurrence of apoptosis in the CA IX-positive cell subpopulation than in the CA IX-negative one. We also demonstrated that the cell-surface CA IX level dropped during the death progress due to an increased ECD shedding, which required a functional ADAM17. Inhibitors of metalloproteinases reduced CA IX ECD shedding, but not apoptosis. The CA IX ECD release induced by cytotoxic drugs was connected to elevated expression of CA IX in the surviving fraction of cells. Moreover, an externally added recombinant CA IX ECD activated a pathway driven by the Nanog transcription factor implicated in epithelial-mesenchymal transition and stemness. CONCLUSIONS: These findings imply that the increased level of the circulating CA IX ECD might be useful as an indicator of an effective antitumor chemotherapy. Conversely, elevated CA IX ECD might generate unwanted effects through autocrine/paracrine signaling potentially contributing to resistance and tumor progression.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000331
003      
CZ-PrNML
005      
20200121105103.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-016-2267-4 $2 doi
024    7_
$a 10.1186/s12885-016-2267-4 $2 doi
035    __
$a (PubMed)26993100
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vidlickova, Ivana $u Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovak Republic. Department of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia.
245    10
$a Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy / $c I. Vidlickova, F. Dequiedt, L. Jelenska, O. Sedlakova, M. Pastorek, S. Stuchlik, J. Pastorek, M. Zatovicova, S. Pastorekova,
520    9_
$a BACKGROUND: Carbonic anhydrase IX (CA IX) is a tumor-associated, highly active, transmembrane carbonic anhydrase isoform regulated by hypoxia and implicated in pH control and adhesion-migration-invasion. CA IX ectodomain (ECD) is shed from the tumor cell surface to serum/plasma of patients, where it can signify cancer prognosis. We previously showed that the CA IX ECD release is mediated by disintegrin and metalloproteinase ADAM17. Here we investigated the CA IX ECD shedding in tumor cells undergoing apoptosis in response to cytotoxic drugs, including cycloheximide and doxorubicin. METHODS: Presence of cell surface CA IX was correlated to the extent of apoptosis by flow cytometry in cell lines with natural or ectopic CA IX expression. CA IX ECD level was assessed by ELISA using CA IX-specific monoclonal antibodies. Effect of recombinant CA IX ECD on the activation of molecular pathways was evaluated using the cell-based dual-luciferase reporter assay. RESULTS: We found a significantly lower occurrence of apoptosis in the CA IX-positive cell subpopulation than in the CA IX-negative one. We also demonstrated that the cell-surface CA IX level dropped during the death progress due to an increased ECD shedding, which required a functional ADAM17. Inhibitors of metalloproteinases reduced CA IX ECD shedding, but not apoptosis. The CA IX ECD release induced by cytotoxic drugs was connected to elevated expression of CA IX in the surviving fraction of cells. Moreover, an externally added recombinant CA IX ECD activated a pathway driven by the Nanog transcription factor implicated in epithelial-mesenchymal transition and stemness. CONCLUSIONS: These findings imply that the increased level of the circulating CA IX ECD might be useful as an indicator of an effective antitumor chemotherapy. Conversely, elevated CA IX ECD might generate unwanted effects through autocrine/paracrine signaling potentially contributing to resistance and tumor progression.
650    _2
$a protein ADAM17 $x genetika $x metabolismus $7 D000072198
650    _2
$a monoklonální protilátky $x aplikace a dávkování $7 D000911
650    _2
$a apoptóza $x účinky léků $x genetika $7 D017209
650    _2
$a karboanhydrasa IX $x aplikace a dávkování $x genetika $x metabolismus $7 D000071231
650    _2
$a hypoxie buňky $x genetika $7 D015687
650    _2
$a cykloheximid $x aplikace a dávkování $7 D003513
650    _2
$a epitelo-mezenchymální tranzice $x genetika $7 D058750
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory $x genetika $x patologie $7 D009369
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dequiedt, Franck $u Cellular and Molecular Biology Unit, Gembloux Agro-Bio Tech, University of Liege, Liege, Belgium.
700    1_
$a Jelenska, Lenka $u Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovak Republic.
700    1_
$a Sedlakova, Olga $u Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovak Republic.
700    1_
$a Pastorek, Michal $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Stuchlik, Stanislav $u Department of Molecular Biology, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia.
700    1_
$a Pastorek, Jaromir $u Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovak Republic.
700    1_
$a Zatovicova, Miriam $u Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovak Republic.
700    1_
$a Pastorekova, Silvia $u Department of Molecular Medicine, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 845 05, Bratislava, Slovak Republic. silvia.pastorekova@savba.sk. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. silvia.pastorekova@savba.sk.
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 16, č. - (2016), s. 239
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26993100 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20200121105440 $b ABA008
999    __
$a ok $b bmc $g 1179471 $s 960898
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 16 $c - $d 239 $e 20160319 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options